0 Ratings
ID

43903

Description

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM; ODM derived from: https://clinicaltrials.gov/show/NCT02301806

Link

https://clinicaltrials.gov/show/NCT02301806

Keywords

Versions (2)
  1. 6/29/16 6/29/16 -
  2. 9/20/21 9/20/21 -
Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility Type 2 Diabetes NCT02301806

    English

    Eligibility Type 2 Diabetes NCT02301806

    1 forms  
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    provision of informed consent before any study specific procedures
    Description

    Informed consent

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    type ii diabetes who have inadequate glycaemic control (6.5%≦hba1c＜9.0%)
    Description

    Diabetes Mellitus, Non-Insulin-Dependent Poor glycemic control

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0011860
    UMLS CUI [1,2]
    C0342299
    age from 20 to 80 years old
    Description

    Age

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    no history of using any antihyperglycemic drugs
    Description

    Hypoglycemic Agents Not used

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0020616
    UMLS CUI [1,2]
    C0445107
    no history of cardiovascular complications
    Description

    Cardiac complication Absent

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0161816
    UMLS CUI [1,2]
    C0332197
    no treatment or treatment with stable doses of lipid-lowering, antihypertensive, and antiplatelet agents for at least 3 months prior to randomization
    Description

    Antilipemic agent Therapeutic procedure Absent | Antilipemic agent Therapeutic procedure Dosage Stable | Antihypertensive Agents Therapeutic procedure Absent | Antihypertensive Agents Therapeutic procedure Dosage Stable | Antiplatelet Agents Therapeutic procedure Absent | Antiplatelet Agents Therapeutic procedure Dosage Stable

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0086440
    UMLS CUI [1,2]
    C0087111
    UMLS CUI [1,3]
    C0332197
    UMLS CUI [2,1]
    C0086440
    UMLS CUI [2,2]
    C0087111
    UMLS CUI [2,3]
    C0178602
    UMLS CUI [2,4]
    C0205360
    UMLS CUI [3,1]
    C0003364
    UMLS CUI [3,2]
    C0087111
    UMLS CUI [3,3]
    C0332197
    UMLS CUI [4,1]
    C0003364
    UMLS CUI [4,2]
    C0087111
    UMLS CUI [4,3]
    C0178602
    UMLS CUI [4,4]
    C0205360
    UMLS CUI [5,1]
    C0085826
    UMLS CUI [5,2]
    C0087111
    UMLS CUI [5,3]
    C0332197
    UMLS CUI [6,1]
    C0085826
    UMLS CUI [6,2]
    C0087111
    UMLS CUI [6,3]
    C0178602
    UMLS CUI [6,4]
    C0205360
    4.5 % ≤ fasting fmd at baseline < 8.0 %
    Description

    Diet therapy Fasting Imitation

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0012159
    UMLS CUI [1,2]
    C0015663
    UMLS CUI [1,3]
    C3826143
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    ・type i diabetes
    Description

    Diabetes Mellitus, Insulin-Dependent

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0011854
    pregnancy
    Description

    Pregnancy

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0032961
    liver disease (hepatic enzymes more than three times the upper limit of normal ranges)
    Description

    Liver disease Elevated liver enzymes

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0023895
    UMLS CUI [1,2]
    C0235996
    impairared kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women)
    Description

    Renal Insufficiency | Creatinine measurement, serum | Gender

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C1565489
    UMLS CUI [2]
    C0201976
    UMLS CUI [3]
    C0079399
    cigarette smokers
    Description

    Cigarette smoker

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0337667
    contraindications to glimepiride and sitagliptin
    Description

    Medical contraindication glimepiride | Medical contraindication sitagliptin

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C1301624
    UMLS CUI [1,2]
    C0061323
    UMLS CUI [2,1]
    C1301624
    UMLS CUI [2,2]
    C1565750
    active proliferative diabetic retinopathy
    Description

    Proliferative diabetic retinopathy

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0154830
    Back to the top of the page

    Similar models

    Eligibility Type 2 Diabetes NCT02301806

    1 forms
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Informed consent
    Item
    provision of informed consent before any study specific procedures
    boolean
    C0021430 (UMLS CUI [1])
    Diabetes Mellitus, Non-Insulin-Dependent Poor glycemic control
    Item
    type ii diabetes who have inadequate glycaemic control (6.5%≦hba1c＜9.0%)
    boolean
    C0011860 (UMLS CUI [1,1])
    C0342299 (UMLS CUI [1,2])
    Age
    Item
    age from 20 to 80 years old
    boolean
    C0001779 (UMLS CUI [1])
    Hypoglycemic Agents Not used
    Item
    no history of using any antihyperglycemic drugs
    boolean
    C0020616 (UMLS CUI [1,1])
    C0445107 (UMLS CUI [1,2])
    Cardiac complication Absent
    Item
    no history of cardiovascular complications
    boolean
    C0161816 (UMLS CUI [1,1])
    C0332197 (UMLS CUI [1,2])
    Antilipemic agent Therapeutic procedure Absent | Antilipemic agent Therapeutic procedure Dosage Stable | Antihypertensive Agents Therapeutic procedure Absent | Antihypertensive Agents Therapeutic procedure Dosage Stable | Antiplatelet Agents Therapeutic procedure Absent | Antiplatelet Agents Therapeutic procedure Dosage Stable
    Item
    no treatment or treatment with stable doses of lipid-lowering, antihypertensive, and antiplatelet agents for at least 3 months prior to randomization
    boolean
    C0086440 (UMLS CUI [1,1])
    C0087111 (UMLS CUI [1,2])
    C0332197 (UMLS CUI [1,3])
    C0086440 (UMLS CUI [2,1])
    C0087111 (UMLS CUI [2,2])
    C0178602 (UMLS CUI [2,3])
    C0205360 (UMLS CUI [2,4])
    C0003364 (UMLS CUI [3,1])
    C0087111 (UMLS CUI [3,2])
    C0332197 (UMLS CUI [3,3])
    C0003364 (UMLS CUI [4,1])
    C0087111 (UMLS CUI [4,2])
    C0178602 (UMLS CUI [4,3])
    C0205360 (UMLS CUI [4,4])
    C0085826 (UMLS CUI [5,1])
    C0087111 (UMLS CUI [5,2])
    C0332197 (UMLS CUI [5,3])
    C0085826 (UMLS CUI [6,1])
    C0087111 (UMLS CUI [6,2])
    C0178602 (UMLS CUI [6,3])
    C0205360 (UMLS CUI [6,4])
    Diet therapy Fasting Imitation
    Item
    4.5 % ≤ fasting fmd at baseline < 8.0 %
    boolean
    C0012159 (UMLS CUI [1,1])
    C0015663 (UMLS CUI [1,2])
    C3826143 (UMLS CUI [1,3])
    Item Group
    C0680251 (UMLS CUI)
    Diabetes Mellitus, Insulin-Dependent
    Item
    ・type i diabetes
    boolean
    C0011854 (UMLS CUI [1])
    Pregnancy
    Item
    pregnancy
    boolean
    C0032961 (UMLS CUI [1])
    Liver disease Elevated liver enzymes
    Item
    liver disease (hepatic enzymes more than three times the upper limit of normal ranges)
    boolean
    C0023895 (UMLS CUI [1,1])
    C0235996 (UMLS CUI [1,2])
    Renal Insufficiency | Creatinine measurement, serum | Gender
    Item
    impairared kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women)
    boolean
    C1565489 (UMLS CUI [1])
    C0201976 (UMLS CUI [2])
    C0079399 (UMLS CUI [3])
    Cigarette smoker
    Item
    cigarette smokers
    boolean
    C0337667 (UMLS CUI [1])
    Medical contraindication glimepiride | Medical contraindication sitagliptin
    Item
    contraindications to glimepiride and sitagliptin
    boolean
    C1301624 (UMLS CUI [1,1])
    C0061323 (UMLS CUI [1,2])
    C1301624 (UMLS CUI [2,1])
    C1565750 (UMLS CUI [2,2])
    Proliferative diabetic retinopathy
    Item
    active proliferative diabetic retinopathy
    boolean
    C0154830 (UMLS CUI [1])
    Back to the top of the page 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial